Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty

American Journal of Epidemiology

Volumn 165, Issue 7, 2007, Pages 762-775

  Van De Velde, Nicolas ^a   Brisson, Marc ^a,b,d   Boily, Marie Claude ^a,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Cancer vaccines; Computer simulation; Models, theoretical; Papillomavirus infections; Papillomavirus vaccines; Uncertainty; Uterine cervical neoplasms; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CANCER; COHORT ANALYSIS; COMPUTER SIMULATION; EFFICIENCY MEASUREMENT; QUANTITATIVE ANALYSIS; TUMOR; UNCERTAINTY ANALYSIS; VACCINATION; VACCINE; VIRAL DISEASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; MAJOR CLINICAL STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; VIRUS STRAIN; WART VIRUS;

ADOLESCENT; ADULT; CARCINOMA, SQUAMOUS CELL; CHILD; COMPUTER SIMULATION; FEMALE; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNCERTAINTY; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 33947227220     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwk059     Document Type: Article

References (110)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19:1-5.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
4. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
6. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
7. Spano JP, Marcelin AG, Carcelin G. HPV and cancer. (In French). Bull Cancer 2005;92:59-64.
8. Bonvicini F, Venturoli S, Ambretti S, et al. Presence and type of oncogenic human papillomavirus in classic and in differentiated vulvar intraepithelial neoplasia and keratinizing vulvar squamous cell carcinoma. J Med Virol 2005;77:102-6.
9. Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-70.
10. Huang FY, Kwok YK, Lau ET, et al. Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet 2005;157:42-8.
11. Rufforny I, Wilkinson EJ, Liu C, et al. Human papillomavirus infection and p16(INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. J Low Genit Tract Dis 2005;9:108-13.
12. Gagne SE, Jensen R, Polvi A, et al. High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia. J Acquir Immune Defic Syndr 2005;40:182-9.
13. Dianzani C, Calvieri S, Pierangeli A, et al. Identification of human papilloma viruses in male dysplastic genital lesions. New Microbiol 2004;27:65-9.
14. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl) 2004;193:35-44.
15. Newton R, Bousarghin L, Ziegler J, et al. Human papillomaviruses and cancer in Uganda. Eur J Cancer Prev 2004;13:113-18.
16. Salazar EL, Mercado E, Calzada L. Human papillomavirus HPV-16 DNA as an epitheliotropic virus that induces hyperproliferation in squamous penile tissue. Arch Androl 2005;51:327-34.
17. Clayman GL, Stewart MG, Weber RS, et al. Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg 1994;120:743-8.
18. de Villiers EM, Weidauer H, Otto H, et al. Papillomavirus DNA in human tongue carcinomas. Int J Cancer 1985;36:575-8.
19. Kashima HK, Kutcher M, Kessis T, et al. Human papillomavirus in squamous cell carcinoma, leukoplakia, lichen planus, and clinically normal epithelium of the oral cavity. Ann Otol Rhinol Laryngol 1990;99:55-61.
20. Mao EJ, Schwartz SM, Daling JR, et al. Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Int J Cancer 1996;69:152-8.
21. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 1998;20:250-65.
22. Paz IB, Cook N, Odom-Maryon T, et al. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997;79:595-604.
23. Snijders PJ, Cromme FV, van den Brule AJ, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 1992;51:845-50.
24. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.
25. von Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162-8.
26. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403.
27. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27.
28. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
29. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
30. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
31. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
32. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
33. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
34. US Food and Drug Administration. Center for Biologics Evaluation and Research. Product approval information. Licensing action. GARDASIL. Label. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine 9682300 (Accessed June 8, 2006); STN: 125126/0. (http://www.fda.gov/cber/ products/hpvmer060806.htm).
35. Health Canada. Drugs and health products. Notice of compliance (NOC). Gardasil. Recombinant human papillomavirus vaccine (types 6, 11, 16, 18). DIN: 02283190. (Accessed July 10, 2006). (http://www.hc-sc.gc.ca/dhp-mps/alt_formats/ hpfb-dgpsa/txt/prodpharma/bio2006et.txt).
36. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6.
37. Lowndes CM, Gill ON. Cervical cancer, human papillomavirus, and vaccination. BMJ 2005;331:915-16.
38. Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 2005;308:618-21.
39. Alary M, Lowndes CM, Boily MC. Community randomized trials for HIV prevention: the past, a lesson for the future? AIDS 2003;17:2661-3.
40. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191(suppl 1):S97-106.
41. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003;106:896-904.
42. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.
43. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13:631-9.
44. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
45. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-48.
46. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.
47. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006;3:e138.
48. Liu T, Soong SJ, Alvarez RD, et al. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev 1995;4:373-80.
49. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.
50. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003;127:930-4.
51. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-102.
52. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7.
53. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
54. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
55. Rousseau MC, Pereira JS, Prado JC, et al. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508-17.
56. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
57. Bollen LJ, Tjong AHS, van der Velden J, et al. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis 1997;24:456-60.
58. Elfgren K, Jacobs M, Walboomers JM, et al. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002;100(5 pt 1):965-71.
59. Kanamori Y, Kigawa J, Minagawa Y, et al. Residual disease and presence of human papillomavirus after conization. Oncology 1998;55:517-20.
60. Kjellberg L, Wadell G, Bergman F, et al. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol 2000;183:1238-42.
61. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:737-44.
62. Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;91:626-31.
63. Nagai Y, Maehama T, Asato T, et al. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000;79:294-9.
64. Sarian LO, Derchain SF, Pitta DR, et al. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J Clin Virol 2004;31:270-4.
65. Strand A, Wilander E, Zehbe I, et al. High risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia. Acta Obstet Gynecol Scand 1997;76:140-4.
66. Wierrani F. Experimental investigations and clinical use of photodynamic therapy (PDT) in the Rudolf Foundation Hospital. (In German). Gynakol Geburtshilfliche Rundsch 1999;39:217-25.
67. Iman RL, Helton JC, Campbell JE. An approach to sensitivity analysis of computer models: part I - introduction, input variable selection and preliminary variable assessment. J Quality Technol 1981;13:174-83.
68. Health Canada. Cervical cancer screening in Canada: 1998 surveillance report. 2002. (http://www.phac-aspc.gc.ca/publicat/ccsic-dccuac/index.html).
69. Brisson M, Boily MC, Masse BR, et al. Highlights of the sexual activity of the heterosexual population in the province of Quebec. Sex Transm Infect 1999;75:296-9.
70. Canada Statistics, 2002. (http://www.statcan.ca/english/freepub/ 84F0211XIE/2002/tables.htm).
71. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-19.
72. Howard M, Sellors J, Lytwyn A. Cervical intraepithelial neoplasia in women presenting with external genital warts. CMAJ 2002;166:598-9.
73. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000;163:503-8.
74. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403.
75. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
76. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
77. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
78. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485-90.
79. Syrjänen S, Shabalova I, Petrovichev N, et al. Acquisition of high-risk human papillomavirus infections and pap smear abnormalities among women in the New Independent States of the Former Soviet Union. J Clin Microbiol 2004;42:505-11.
80. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
81. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-92.
82. Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998;25:243-50.
83. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.
84. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-43.
85. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
86. Richardson H, Franco E, Pintos J, et al. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis 2000;27:79-86.
87. Sellors JW, Karwalajtys TL, Kaczorowski JA, et al. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ 2002;167:871-3.
88. Ontario Cancer Registry Report, 1999. (http://www.cancercare.on.ca/ documents/CervicalCancerinOntario.pdf).
89. British Columbia Annual Report, 2003. (http://www.bccancer.bc.ca/PPI/ Screening/Cervical/2004+CCSP+Annual+Report.htm).
90. Manitoba Cancer Care Report, 2004. (http://www.cancercare.mb.ca/MCCSP/ pdfs/cc&pt_utilisation_1970_1999.pdf).
91. Public Health Agency of Canada, 2005. (http://dsol-smed.phac-aspc.gc.ca/ dsol-smed/cancer/c_age_e.html).
92. Liu S, Semenciw R, Probert A, et al. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001;11:24-31.
93. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004;191:105-13.
94. Centers for Disease Control. National Breast and Cervical Cancer Early Detection Program (NBCCEDP): 1991-2002 National Report. 2004. (http://www.cdc.gov/cancer/nbccedp/bccpdfs/national_report.pdf).
95. Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006;119:615-23.
96. Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-16.
97. Maticka-Tyndale E. Sexual health and Canadian youth: how do we measure up? Can J Hum Sexuality 2001;10:1-17.
98. Jamison JH, Kaplan DW, Hamman R, et al. Spectrum of genital human papillomavirus infection in a female adolescent population. Sex Transm Dis 1995;22:236-43.
99. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
100. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
101. Rohan T, Mann V, McLaughlin J, et al. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. Int J Cancer 1991;49:856-60.
102. Aoyama C, Peters J, Senadheera S, et al. Uterine cervical dysplasia and cancer: identification of c-myc status by quantitative polymerase chain reaction. Diagn Mol Pathol 1998;7:324-30.
103. Evans MF, Mount SL, Beatty BG, et al. Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Mod Pathol 2002;15:1339-47.
104. Feoli-Fonseca JC, Oligny LL, Brochu P, et al. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. J Med Virol 2001;63:284-92.
105. Isacson C, Kessis TD, Hedrick L, et al. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996;56:669-74.
106. Quade BJ, Park JJ, Crum CP, et al. In vivo cyclin E expression as a marker for early cervical neoplasia. Mod Pathol 1998;11:1238-46.
107. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
108. British Columbia 2003 statistics, 2005. (http://www.bccancer.bc.ca/HPI/ CancerStatistics/FF/CaType/CE.htm#cervix).
109. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003;168:421-5.
110. Spear RC. Large simulation models: calibration, uniqueness and goodness of fit. Environ Model Software 1997;12:219-28.